SUROVA study: global real-world treatment strategies and
mortality risk prediction in advanced ovarian cancer

J 2025

SUROVA study: global real-world treatment strategies and mortality risk prediction in advanced ovarian cancer

CHIVA, Luis; Pilar ORDAS; Jagannath MISHRA; Ali AYHAN; Yoo-Young LEE et al.

Základní údaje

Originální název

SUROVA study: global real-world treatment strategies and mortality risk prediction in advanced ovarian cancer

Autoři

CHIVA, Luis; Pilar ORDAS; Jagannath MISHRA; Ali AYHAN; Yoo-Young LEE; Giorgio BOGANI; Somashekhar SP; Marta LOMNYTSKA; Maciej STUKAN; Robert FRUSCIO; Bernabe Fora CHURA; Rosa A SALCEDO-HERNANDEZ; De Iaco PIERANDREA; Dimitrios HAIDOPOULOS; Valentyn SVINTSITSKIY; Vandana JAIN; Paul STANCIU; Friederike Luise RAWERT; Celal AKDEMIR; Reem ABDALLAH; Enrique CHACON; Jose Angel MINGUEZ; Antonio GIL-MORENO; Kateryna KHARCHENKO; Malihe Hasanzadeh MOFRAD; Gerhard GEBAUER; Berta DIAZ-FEIJOO; Giuseppe SCIBILIA; Marko KLARIC; Erik SKOF; Abu Saadeh FERAS; Michael D MUELLER; Sami SAARELAINEN; Alvaro Tejerizo GARCIA; Christina FOTOPOULOU; Pluvio CORONADO; Fuat DERMIKIRAN; Frederic GOFFIN; Dimitrios TSOLAKIDIS a Antonio GONZALEZ-MARTIN

Vydání

International journal of gynecological cancer, LONDON, BMJ PUBLISHING GROUP, 2025, 1048-891X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 4.700 v roce 2024

Označené pro přenos do RIV

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1016/j.ijgc.2025.102688

UT WoS

001638182000002

Klíčová slova anglicky

Ovarian Cancer; Primary Debulking Surgery; Neoadjuvant Chemotherapy; Real-World Data; Survival Analysis

Změněno: 30. 3. 2026 12:49, Mgr. Tereza Miškechová

Anotace

V originále

Objective: This study aimed to compare 5-year overall survival between primary debulking surgery and neoadjuvant chemotherapy followed by interval surgery in patients with stage IIIB to IVB epithelial ovarian cancer, using global real-world data. Secondary objectives included evaluation of progression-free survival and the influence of race, post-operative complications, and residual disease. Methods: SUROVA is a retrospective, international cohort study involving patients treated between 2018 and 2019 across 174 centers in 55 countries. Patients underwent primary surgery or received neoadjuvant chemotherapy followed by interval surgery, per institutional protocols. Propensity score matching was based on 7 baseline variables: age, race, Eastern Cooperative Oncology Group performance status at diagnosis, CA125 level at diagnosis, FIGO (International Federation of Gynecology and Obstetrics) stage IV disease, presence of ascites, and final tumor grade. Cox regression models with time-dependent effects and interaction terms were applied. A clinical risk calculator was developed and internally validated. Results: A total of 3286 patients had a mean age of 60.0 years (SD 12); 2978 (90.6%) had high-grade serous carcinoma, and 795 (24.7%) presented with FIGO stage IV disease. A total of 1666 patients (50.7%) underwent primary cytoreductive surgery, and 1620 (49.3%) received neoadjuvant chemotherapy. The median follow-up duration was 43.8 months (interquartile range; 22.6-59.3). After propensity score matching (n=1524), overall survival was similar between groups (67.2 vs 65.0 months; HR 1.002, 95% CI 0.85 to 1.18, p=.98). Outcomes differed by ethnicity, residual disease, and post-operative complications. Post-operative complications (28%) significantly worsened survival (66 vs 46 months; HR 1.5, 95% CI 1.2 to 1.9, p<.001), especially among patients undergoing primary surgery (73 vs 46 months; HR 1.85, 95% CI 1.43 to 2.37, p<.001). The most favorable outcomes were observed among patients with primary surgery, complete resection, and no complications, with median overall survival not reached (HR 1.25, 95% CI 1.12 to 1.40, p<.001). Conclusions: Although overall survival was similar between groups, treatment effects differed by ethnicity, residual disease, and complications. Post-operative complications were associated with significantly worse survival, particularly among patients undergoing primary surgery, while the best outcomes were achieved in those who had primary surgery with complete resection and no complications.

Citovat

@article{2563843,
   author = {Chiva, Luis and Ordas, Pilar and Mishra, Jagannath and Ayhan, Ali and Lee, YooandYoung and Bogani, Giorgio and Sp, Somashekhar and Lomnytska, Marta and Stukan, Maciej and Fruscio, Robert and Chura, Bernabe Fora and SalcedoandHernandez, Rosa A and Pierandrea, De Iaco and Haidopoulos, Dimitrios and Svintsitskiy, Valentyn and Jain, Vandana and Stanciu, Paul and Rawert, Friederike Luise and Akdemir, Celal and Abdallah, Reem and Chacon, Enrique and Minguez, Jose Angel and GilandMoreno, Antonio and Kharchenko, Kateryna and Mofrad, Malihe Hasanzadeh and Gebauer, Gerhard and DiazandFeijoo, Berta and Scibilia, Giuseppe and Klaric, Marko and Skof, Erik and Feras, Abu Saadeh and Mueller, Michael D and Saarelainen, Sami and Garcia, Alvaro Tejerizo and Fotopoulou, Christina and Coronado, Pluvio and Dermikiran, Fuat and Goffin, Frederic and Tsolakidis, Dimitrios and GonzalezandMartin, Antonio},
   article_location = {LONDON},
   article_number = {12},
   doi = {https://doi.org/10.1016/j.ijgc.2025.102688},
   keywords = {Ovarian Cancer; Primary Debulking Surgery; Neoadjuvant Chemotherapy; Real-World Data; Survival Analysis},
   language = {eng},
   issn = {1048-891X},
   journal = {International journal of gynecological cancer},
   title = {SUROVA study: global real-world treatment strategies and mortality risk prediction in advanced ovarian cancer},
   volume = {35},
   year = {2025}
}

TY  - JOUR
ID  - 2563843
AU  - Chiva, Luis - Ordas, Pilar - Mishra, Jagannath - Ayhan, Ali - Lee, Yoo-Young - Bogani, Giorgio - Sp, Somashekhar - Lomnytska, Marta - Stukan, Maciej - Fruscio, Robert - Chura, Bernabe Fora - Salcedo-Hernandez, Rosa A - Pierandrea, De Iaco - Haidopoulos, Dimitrios - Svintsitskiy, Valentyn - Jain, Vandana - Stanciu, Paul - Rawert, Friederike Luise - Akdemir, Celal - Abdallah, Reem - Chacon, Enrique - Minguez, Jose Angel - Gil-Moreno, Antonio - Kharchenko, Kateryna - Mofrad, Malihe Hasanzadeh - Gebauer, Gerhard - Diaz-Feijoo, Berta - Scibilia, Giuseppe - Klaric, Marko - Skof, Erik - Feras, Abu Saadeh - Mueller, Michael D - Saarelainen, Sami - Garcia, Alvaro Tejerizo - Fotopoulou, Christina - Coronado, Pluvio - Dermikiran, Fuat - Goffin, Frederic - Tsolakidis, Dimitrios - Gonzalez-Martin, Antonio
PY  - 2025
TI  - SUROVA study: global real-world treatment strategies and mortality risk prediction in advanced ovarian cancer
JF  - International journal of gynecological cancer
VL  - 35
IS  - 12
PB  - BMJ PUBLISHING GROUP
SN  - 1048891X
KW  - Ovarian Cancer
KW  - Primary Debulking Surgery
KW  - Neoadjuvant Chemotherapy
KW  - Real-World Data
KW  - Survival Analysis
N2  - Objective: This study aimed to compare 5-year overall survival between primary debulking surgery and neoadjuvant chemotherapy followed by interval surgery in patients with stage IIIB to IVB epithelial ovarian cancer, using global real-world data. Secondary objectives included evaluation of progression-free survival and the influence of race, post-operative complications, and residual disease. Methods: SUROVA is a retrospective, international cohort study involving patients treated between 2018 and 2019 across 174 centers in 55 countries. Patients underwent primary surgery or received neoadjuvant chemotherapy followed by interval surgery, per institutional protocols. Propensity score matching was based on 7 baseline variables: age, race, Eastern Cooperative Oncology Group performance status at diagnosis, CA125 level at diagnosis, FIGO (International Federation of Gynecology and Obstetrics) stage IV disease, presence of ascites, and final tumor grade. Cox regression models with time-dependent effects and interaction terms were applied. A clinical risk calculator was developed and internally validated. Results: A total of 3286 patients had a mean age of 60.0 years (SD 12); 2978 (90.6%) had high-grade serous carcinoma, and 795 (24.7%) presented with FIGO stage IV disease. A total of 1666 patients (50.7%) underwent primary cytoreductive surgery, and 1620 (49.3%) received neoadjuvant chemotherapy. The median follow-up duration was 43.8 months (interquartile range; 22.6-59.3). After propensity score matching (n=1524), overall survival was similar between groups (67.2 vs 65.0 months; HR 1.002, 95% CI 0.85 to 1.18, p=.98). Outcomes differed by ethnicity, residual disease, and post-operative complications. Post-operative complications (28%) significantly worsened survival (66 vs 46 months; HR 1.5, 95% CI 1.2 to 1.9, p<.001), especially among patients undergoing primary surgery (73 vs 46 months; HR 1.85, 95% CI 1.43 to 2.37, p<.001). The most favorable outcomes were observed among patients with primary surgery, complete resection, and no complications, with median overall survival not reached (HR 1.25, 95% CI 1.12 to 1.40, p<.001). Conclusions: Although overall survival was similar between groups, treatment effects differed by ethnicity, residual disease, and complications. Post-operative complications were associated with significantly worse survival, particularly among patients undergoing primary surgery, while the best outcomes were achieved in those who had primary surgery with complete resection and no complications.
ER  -

Přehled o publikaci